Will we have a treatment for Alzheimer's disease that halts the progression of the disease by 2035?
Gezondheid en geneeskundeOne-Off8jManifold MarketsGeen KYCGeverifieerde afwikkelingsgegevensGoed gekalibreerdHuidige gemeenschapsvoorspellingNee 70%
Voorspellers
8
Vraagtype
binary
Methodologie
Play-money forecasting platform
Brontype
Voorspelling
Marktdata
Bijgewerkt 13 uur geleden
Verouderd13 nov 24, 12:49 UTC1 jan 35, 22:59 UTC
Trends
Regels
Alzheimer's disease is thought to be caused by the abnormal build-up of proteins in and around brain cells, namely beta-amyloid plaques and tau tangles.
- Currently, there are two anti-amyloid treatments for early AD, Leqembi (lecanemab) and Kisunla (donanemab).
- They show a 27.1% [1] and 31.8% [2] reduction in disease progression compared to placebo over 18 months.
- Will we a treatment that shows a 90% reduction in disease progression over 18 months by 2035?
- The treatment must be FDA approved and the disease progression must be characterized by an approved rating like Clinical Dementia Rating – Sum of Boxes (CDR-SB) or Integrated Alzheimer’s Disease Rating Scale (iADRS).
- The treatment can be of any kind (small molecule, antibody, gene therapy), but must comparable in "curing" the disease rather than treating the symptoms.
